Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Minority Smokers
Interventions: Patient Navigator; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 2
States / cities: New York, New York

Conditions: HFrEF - Heart Failure With Reduced Ejection Fraction, Heart Failure, Heart Failure, Systolic, Heart Diseases
Interventions: beta blockers, StudyU Application; Drug · Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Ipatasertib, Itraconazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Colon Polyps
Interventions: Educational Training; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Acute Myocardial Infarction (AMI), Coronary Occlusion, Acute Coronary Syndrome
Interventions: Guardian System; Device
Lead sponsor: Angel Medical Systems; Industry
Eligibility: 21 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 85 more

Conditions: Prostate Cancer
Interventions: enzastaurin, placebo, docetaxel, prednisone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 22
States / cities: Fullerton, California • Los Angeles, California • Northridge, California + 19 more

Conditions: Diabetes, Type I
Interventions: Technosphere Insulin, Active comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 589 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more

Conditions: Seborrheic Dermatitis
Interventions: ketoconazole 2% foam, ketoconazole 2% shampoo; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Digestive Discomfort
Interventions: Dietary Supplement: conventional cow's milk consumption, and then A1PF milk consumption, Dietary Supplement: A1PF milk consumption, and then conventional cow's milk consumption; Other
Lead sponsor: a2 Milk Company Ltd.; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Eosinophilic Esophagitis
Interventions: AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension; Drug
Lead sponsor: AQILION AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Parkinson's Disease
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Autism Spectrum Disorder, Dental Caries
Interventions: video modeled social story; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 5 Years to 14 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Epiphora
Interventions: Atropine sulfate ophthalmic solution 0.005%, Vehicle arm; Drug
Lead sponsor: Rehan Ahmed; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Houston, Texas • Mesquite, Texas

Conditions: Hyperhidrosis
Interventions: Botulinum Toxin Type A; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Periodontitis
Interventions: PeriZone PerioPatch, Scaling and root planing alone; Device · Procedure
Lead sponsor: MIS Implant Technologies, Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Norfolk, Virginia

Conditions: Healthy Volunteers
Interventions: AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: COVID-19 Infection
Interventions: Magnesium Citrate plus probiotic; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: mobile cognitive behavioral stress management intervention, Diploma in Stress Management course; Behavioral
Lead sponsor: ISA Associates, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Bullous Pemphigoid
Interventions: Rituximab combined with Omalizumab; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Acute Liver Failure, Acute Liver Injury
Interventions: Ornithine Phenylacetate; Drug
Lead sponsor: William Lee; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more

Search by objective public record fields.

Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care

Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

A Prospective Trial of an Endoscopic Quality Improvement Project

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

AngelMed for Early Recognition and Treatment of STEMI

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo

A1 Beta-casein-free Milk in Milk-intolerant Participants

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

The Effect of Donepezil on Gait and Balance in Parkinson's Disease

Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder

Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Clinical Trial of PeriZone PerioPatch in Subjects With Chronic Periodontitis

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

"CHANGE COVID-19 Severity"

Using Mobile Stress Management to Reduce Hypertension in African American Men

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury